Table 2 Maspin expression in prostate cancer
From: Role of maspin in cancer
Authors | Years | N. patients | Maspin expression | Clinical features/prognosis |
|---|---|---|---|---|
Lovric et al. | 2010 | 34 prostate cancer | 79% positive maspin with nuclear expression | |
Riddick et al. | 2005 | 44 prostate cancer | Not found | Positive maspin = lower Gleason score |
Machtens et al. | 2001 | 84 prostate cancer | 58% positive maspin | Positive maspin = OS: 78 months, PFS: 41 months, GIII-IV: 23%, N1/N2: 9% OS = 62 months, PFS = 26 months, GIII-IV = 48%, N1/N2 = 18% |
18% negative maspin | ||||
Zou et al. | 2002 | 97 prostate cancer | 40.2% positive maspin | Positive maspin = 91.7% partial response with neoadjuvant therapy |
49.8% negative maspin |